tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Dynavax sees FY25 adjusted EBITDA ‘at least $75M’ vs. $51.9M in FY24

FY25 HEPLISAV-B net product revenue is expected in the range of $305M to $325M

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1